Last reviewed · How we verify
Zoster Vaccine Recombinant
This recombinant zoster vaccine stimulates the immune system to prevent herpes zoster (shingles) by inducing varicella-zoster virus (VZV)-specific cell-mediated and humoral immunity.
This recombinant zoster vaccine stimulates the immune system to prevent herpes zoster (shingles) by inducing varicella-zoster virus (VZV)-specific cell-mediated and humoral immunity. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of post-herpetic neuralgia.
At a glance
| Generic name | Zoster Vaccine Recombinant |
|---|---|
| Also known as | Shingrix |
| Sponsor | University of Colorado, Denver |
| Drug class | Recombinant subunit vaccine |
| Target | Varicella-zoster virus glycoprotein E (gE) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains recombinant VZV glycoprotein E (gE) combined with an AS01B adjuvant system that enhances immune response. It works by priming both CD8+ T cells and antibody-producing B cells against VZV, providing durable protection against reactivation of latent virus that causes shingles and post-herpetic neuralgia.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of post-herpetic neuralgia
Common side effects
- Injection site erythema
- Injection site pain
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients (PHASE4)
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) (PHASE3)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
- Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation (PHASE2)
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zoster Vaccine Recombinant CI brief — competitive landscape report
- Zoster Vaccine Recombinant updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI